Evidence map›Paper›PMID 40369635›Full record

ArticleMicrobial cell factories2025

A highly efficient heterologous expression platform to facilitate the production of microbial natural products in Streptomyces.

Xiuling Wang, Ping Lin, Qiyao Shen, Xueyan Feng, Shouying Xu, Qijun Zhang, Yang Liu, Cailing Ren, Daojing Yong, Qiong Duan and 5 more

Erratum issuedAbstract read
In one paragraph

Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Synthetic and systems biotechnology · 2026
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Xiuling WangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Ping LinDepartment of Natural Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Qingdao University, Qingdao, 266071, China.
Qiyao ShenState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Xueyan FengDepartment of Natural Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Qingdao University, Qingdao, 266071, China.
Shouying XuState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Qijun ZhangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Yang LiuState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Cailing RenState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Daojing YongState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Qiong DuanState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Liujie HuoState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Youming ZhangState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China.
Gang LiDepartment of Natural Medicinal Chemistry and Pharmacognosy, School of Pharmacy, Qingdao University, Qingdao, 266071, China. gang.li@qdu.edu.cn.
Jun FuState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China. fujun@sdu.edu.cn.
Ruijuan LiState Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, China. liruijuan@sdu.edu.cn.

Funding

National Key Research and Development Program of China 2018YFA0900400National Natural Science Foundation of China 32161133013the Shandong Provincial Natural Science Foundation of China ZR2020MC015the Shandong Provincial Natural Science Foundation of China ZR2021ZD39the Shandong Provincial Natural Science Foundation of China ZR2023MC119the State Key Laboratory of Microbial Technology Open Projects Fund Project NO. M2023-15
6 · The paper itself

Abstract

backgroundHeterologous expression in Streptomyces provides a platform for mining natural products (NPs) encoded by cryptic biosynthetic gene clusters (BGCs) of bacteria. The BGCs are first engineered in hosts with robust recombineering systems, such as Escherichia coli, followed by expression in optimized heterologous hosts, such as Streptomyces, with defined metabolic backgrounds.

resultsWe developed a highly efficient heterologous expression platform, named Micro-HEP (microbial heterologous expression platform), that uses versatile E. coli strains capable of both modification and conjugation transfer of foreign BGCs and optimized chassis Streptomyces strain for expression. The stability of repeat sequences in these E. coli strains was superior to that of the commonly used conjugative transfer system E. coli ET12567 (pUZ8002). For optimizing expression of foreign BGCs, the chassis strain S. coelicolor A3(2)-2023 was generated by deleting four endogenous BGCs followed by introducing multiple recombinase-mediated cassette exchange (RMCE) sites in the S. coelicolor A3(2) chromosome. Additionally, modular RMCE cassettes (Cre-lox, Vika-vox, Dre-rox, and phiBT1-attP) were constructed for integrating BGCs into the chassis strain. Micro-HEP was tested using BGCs for the anti-fibrotic compound xiamenmycin and griseorhodins. Two to four copies of the xim BGC were integrated by RMCE, with increasing copy number associated with increasing yield of xiamenmycin. The grh BGC was also efficiently expressed, and the new compound griseorhodin H was identified.

conclusionWe demonstrated that our Micro-HEP system enables the efficient expression of foreign BGCs, facilitating the discovery of new NPs and increasing yields.

Indexed as

Biological ProductsStreptomycesStreptomyces coelicolorEscherichia coliMultigene FamilyBiological ProductsBiosynthetic gene clusterChassis strainHeterologous expressionIntegrationTransfer

Identifiers

PMID40369635
PMCPMC12076808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.